News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Swiss Lonza Group Ltd. Eyes Stake in India Drug Firm, Aptuit Laurus in Deal Valued at $77 Million to $99 Million
March 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss drugs industry supplier Lonza (LONN.VX) is in talks to buy over 51 percent stake in India's Aptuit Laurus in a deal valued at $77 million to $99 million, the Business Standard reported on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
Europe
Lonza
MORE ON THIS TOPIC
Earnings
‘We’re Not Done’: Roche Plans To Sustain Dealmaking Pace After 89bio
October 23, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’
October 23, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Ipsen Puts Up $1.6B To Absorb ImCheck for Mid-Stage Leukemia Antibody
October 22, 2025
·
1 min read
·
Dan Samorodnitsky
Antibody-drug conjugate (ADC)
Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets
October 22, 2025
·
2 min read
·
Tristan Manalac
